These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28673770)

  • 1. Alterations of the nuclear transport system in hepatocellular carcinoma - New basis for therapeutic strategies.
    Beck M; Schirmacher P; Singer S
    J Hepatol; 2017 Nov; 67(5):1051-1061. PubMed ID: 28673770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.
    Ohkoshi S; Yano M; Matsuda Y
    World J Gastroenterol; 2015 Nov; 21(42):12150-6. PubMed ID: 26576099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of nuclear transport: central role in development and transformation?
    Poon IK; Jans DA
    Traffic; 2005 Mar; 6(3):173-86. PubMed ID: 15702986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Insights from Structural Analyses of Ran-GTPase-Driven Nuclear Export of Proteins and RNAs.
    Matsuura Y
    J Mol Biol; 2016 May; 428(10 Pt A):2025-39. PubMed ID: 26519791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NFκB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy.
    Ramesh V; Selvarasu K; Pandian J; Myilsamy S; Shanmugasundaram C; Ganesan K
    Cell Oncol (Dordr); 2016 Dec; 39(6):523-536. PubMed ID: 27562587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma.
    Zamani P; Matbou Riahi M; Momtazi-Borojeni AA; Jamialahmadi K
    Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1301-1313. PubMed ID: 29025272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations in hepatocellular carcinoma: An update.
    Niu ZS; Niu XJ; Wang WH
    World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?
    Pascale RM; Joseph C; Latte G; Evert M; Feo F; Calvisi DF
    DNA Repair (Amst); 2016 Nov; 47():12-20. PubMed ID: 27789167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting nuclear import and export in hematological malignancies.
    Nachmias B; Schimmer AD
    Leukemia; 2020 Nov; 34(11):2875-2886. PubMed ID: 32624581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Review on the associations of signal transducer and activators of transcription 3 with hepatocellular carcinoma].
    Xie JX; Gao QJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 May; 50(5):468-72. PubMed ID: 27141908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of nuclear pore complex in tumor microenvironment and metastasis.
    Funasaka T; Wong RW
    Cancer Metastasis Rev; 2011 Jun; 30(2):239-51. PubMed ID: 21298575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches for the identification of nuclear transport receptor substrates.
    Kimura M; Thakar K; Karaca S; Imamoto N; Kehlenbach RH
    Methods Cell Biol; 2014; 122():353-78. PubMed ID: 24857738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma.
    Lee TK; Cheung VC; Ng IO
    Cancer Lett; 2013 Sep; 338(1):101-9. PubMed ID: 22579789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia inducible factors in hepatocellular carcinoma.
    Chen C; Lou T
    Oncotarget; 2017 Jul; 8(28):46691-46703. PubMed ID: 28493839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.
    Pez F; Lopez A; Kim M; Wands JR; Caron de Fromentel C; Merle P
    J Hepatol; 2013 Nov; 59(5):1107-17. PubMed ID: 23835194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
    Lin D; Wu J
    World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response.
    Burkhart RA; Ronnekleiv-Kelly SM; Pawlik TM
    Surg Oncol; 2017 Jun; 26(2):138-145. PubMed ID: 28577719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.